China National Biotec Group
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From China National Biotec Group
Latest approval gives major US drug maker new foothold in China’s heated and increasingly crowded PD-1 immuno-oncology race.
A top virologist and prominent Chinese researcher sounds alarm over reluctance to clear mRNA vaccines amid regional outbreaks and the government rollout of inactivated virus-based booster shots without real-word evidence.
A new emergency authorization marks China’s fourth approval for inactivated COVID-19 vaccines, despite lingering doubts over the protection offered by the technology and surging cases in one of the most vaccinated countries where Sinopharm’s inactivated vaccines are widely used.
Originated by a Suzhou-based biotech founded two years ago and now being jointly developed with WalVax, China’s first homegrown mRNA COVID-19 vaccine is now entering the final stages of development.